Financial Survey: Glaukos (NYSE:GKOS) versus Holdco Nuvo Group D.G (NASDAQ:NUVO)

Glaukos (NYSE:GKOS) and Holdco Nuvo Group D.G (NASDAQ:NUVO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Valuation & Earnings

This table compares Glaukos and Holdco Nuvo Group D.G”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$314.71 million	22.05	-$134.66 million	($2.88)	-43.85
Holdco Nuvo Group D.G	$180,000.00	31.41	-$33.65 million	N/A	N/A

Holdco Nuvo Group D.G has lower revenue, but higher earnings than Glaukos.

Insider & Institutional Ownership

99.0% of Glaukos shares are held by institutional investors. 6.4% of Glaukos shares are held by insiders. Comparatively, 24.2% of Holdco Nuvo Group D.G shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Glaukos has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Holdco Nuvo Group D.G has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500.

Profitability

This table compares Glaukos and Holdco Nuvo Group D.G’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glaukos	-47.39%	-22.51%	-12.36%
Holdco Nuvo Group D.G	N/A	N/A	-39.84%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Glaukos and Holdco Nuvo Group D.G, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	0	3	8	0	2.73
Holdco Nuvo Group D.G	0	0	0	0	N/A

Glaukos presently has a consensus target price of $129.82, suggesting a potential upside of 2.80%. Given Glaukos’ higher probable upside, equities research analysts plainly believe Glaukos is more favorable than Holdco Nuvo Group D.G.

Summary

Glaukos beats Holdco Nuvo Group D.G on 6 of the 11 factors compared between the two stocks.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

About Holdco Nuvo Group D.G

LAMF Global Ventures Corp. I is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. LAMF Global Ventures Corp. I is based in West Hollywood, California.